Enhancing atrial‐specific gene expression using a calsequestrin <i>cis‐</i>regulatory module <i>4</i> with a sarcolipin promoter

Abstract

For gene therapy involving atrial gene transfer, the CRM4.SLN combination is a promising alternative to the use of the CMV promoter. CRM4.SLN had significant atrial expression and minimized extra-atrial expression.